Introduction
============

Age-related macular degeneration (AMD) is the major cause of central blindness in the elderly in Western countries. It is characterized by a progressive loss of color and fine vision, reduced contrast, and spatiotemporal sensitivity.

Clinically, AMD can be classified into early- or late-atrophic AMD (ie, dry AMD), or exudative (ie, wet) AMD.[@b1-opth-7-437] Wet AMD is characterized by proliferation of choroidal neovascularization. Excessive expression of vascular endothelial growth factor (VEGF) by retinal pigment epithelial (RPE) cells leads to new vessel formation originating from the choroid and extending through defects in the Bruch's membrane and the RPE sub- and intraretinally.[@b2-opth-7-437] Vision loss occurs through the structural and metabolic damage in the retina and in the RPE cells.[@b1-opth-7-437]--[@b3-opth-7-437] To date, anti-VEGF (bevacizumab or ranibizumab) intravitreal injections have been shown to be an effective treatment to decrease retina fluid in exudative AMD.[@b4-opth-7-437],[@b5-opth-7-437] Vision improvement occurs within 1 month and continues to improve over the next few months.

Optical coherence tomography (OCT) is a standard technique for cross-sectional imaging of the retina. OCT is useful in quantitatively evaluating subretinal and intraretinal fluid, assessing possible subfoveal involvement of neovascularization, and in monitoring anti-VEGF intravitreal injection response. Visual evoked potentials (VEP) provide quantitative information on the functional integrity of well-defined visual pathways in the central nervous system. For instance, for analysis of the visual pathways, VEP are considered more sensitive than magnetic resonance imaging in detecting optic neuritis and clinically silent lesions in multiple sclerosis.[@b6-opth-7-437]

We aimed to investigate whether the improved vision by anti-VEGF treatment is reflected in the function of the visual pathways. Our hypothesis was that significant changes in VEP will be observed, and these changes may be related both to improvement in vision and decreased retinal fluid.

Materials and methods
=====================

The interventional case series consisted of six patients having exudative AMD. Diagnosis was based on the best corrected visual acuity (BCVA) testing, full biomicroscopy examination and OCT (Spectral OCT/SLO, Ophthalmic Technologies Inc, Toronto, ON, Canada) analysis in the Department of Ophthalmology, Kuopio University Hospital. For patient characteristics and their visual acuities see [Table 1](#t1-opth-7-437){ref-type="table"}. At the first visit, when exudative AMD diagnosis was made, bevacizumab intravitreal injection was applied into the affected eye of each individual. The injection was performed three times, 6 weeks between injections. VEP, BCVA testing, full biomicroscopy analysis, and OCT examinations were performed at the first visit prior to anti-VEGF injection and 6 weeks after the last (ie, third) injection, about 18 weeks after the first visit. The Ethics Committee of the Kuopio University Hospital had approved the study, and the tenets of the Declaration of Helsinki were followed. All participants provided informed consent.

Visual evoked potentials were recorded using a 64-channel electrode cap (EASYCAP GmbH, Falk-Minow Services, Ammersee, Germany) with the SynAmps2 amplifier (NeuroScan, Inc, El Paso, TX, USA). All scalp electrodes were referred to a midline centrofrontal electrode (FCz). Potentials reflecting eye blinks and vertical eye movements were recorded between electrodes placed above and below the right eye. All electrode impedances were kept below 10 kΩ. Signals were amplified and filtered with a bandpass of 0.1--50 Hz and digitized continuously at 500 Hz.

Pattern reversal VEP were elicited by a high contrast black and white checkerboard stimulus on a computer monitor using STIM2 software (NeuroScan, Inc). To cover the macular area with the stimulus, a circular stimulus field with a diameter of 10.3 degrees was used. The check size was 35 minutes of arc. The pattern was reversed at 1 Hz. A small red fixation target was positioned at two check widths above the center of the pattern stimulus. The viewing distance was 100 cm. Stimulation was monocular after occlusion of the other eye. For each eye and each recording session, responses to two blocks of 120 stimuli were recorded, with an undilated pupil under full refractive correction. Both in the pre- and posttreatment sessions, the eye that was not affected by wet AMD was recorded first. Each patient could clearly perceive the fixation mark with the nonaffected eye. If the patient could not see the fixation mark with the affected eye, he/she was asked to fixate at its known location.

The VEP data were processed offline with SCAN software (NeuroScan, Inc). First, the continuous data from two recording blocks were merged into one file. Then the data were filtered (high pass 1 Hz) and segmented to epochs of 350 ms including a prestimulus interval of 50 ms. Epochs containing blinks or other artifacts were manually rejected. The artifact-free epochs were then averaged separately for each eye and each recording session. In averaging, both the mean and standard deviation were calculated on a point-by-point basis. Responses at electrode Oz were chosen for further analysis.

To test the statistical significance of the changes in VEP between the pre- to posttreatment recordings in each patient, Student's *t*-test was applied to each time point of the VEP waveform. The level of statistical significance was set at *P* \< 0.05. To reduce the probability of interpreting chance fluctuations as true changes, we set an additional requirement for a significant change: the probability level had to be \<0.05 at least in four consecutive data points or at least over 8 ms.

Results
=======

All patients showed improved vision in BCVA after the bevacizumab intravitreal treatment period ([Table 1](#t1-opth-7-437){ref-type="table"}). This was in line with decreased retinal fluid ([Figure 1](#f1-opth-7-437){ref-type="fig"} and [Table 2](#t2-opth-7-437){ref-type="table"}). Each patient's individual images of optical coherence tomography are shown in [Figure 1](#f1-opth-7-437){ref-type="fig"}. For one of the patients (P6), the primarily atrophic AMD changed to exudative form in the left eye during the study period ([Figure 1](#f1-opth-7-437){ref-type="fig"}). This exudative form correlated well with decreased visual acuity and increased retinal thickness ([Figure 1](#f1-opth-7-437){ref-type="fig"} and [Table 1](#t1-opth-7-437){ref-type="table"}). Note that anti-VEGF therapy had only partial improvement for P3 and P6, in whom the reduction in retinal thickness observed in OCT was moderate ([Figure 1](#f1-opth-7-437){ref-type="fig"} and [Table 2](#t2-opth-7-437){ref-type="table"}).

In five out of the six patients, posttreatment VEP waveforms indicated statistically significant changes compared to pretreatment waveforms, and these changes were consistent with improved vision in the treated eye. The VEP of the treated and untreated eyes of each patient before and after anti-VEGF treatment are illustrated in [Figure 2](#f2-opth-7-437){ref-type="fig"}. The changes observed in P100 were decreases in latency and/or increases in amplitude. The time periods of the significant changes in the P100 component, which are consistent with improved vision, are marked with dark grey bars. All these changes were observed in the treated eye. Additional time periods with significant changes were observed outside the target component P100, and they are marked with transparent bars ([Figure 2](#f2-opth-7-437){ref-type="fig"}). Those VEP changes were observed mainly in the eyes in which the treatment effect on P100 was significant, indicating that the whole VEP waveform may be affected. Slowing and/or reduced P100 amplitude was observed in the untreated eye in four out of six cases. The overall result in VEP is illustrated in [Figure 3](#f3-opth-7-437){ref-type="fig"}, where the grand averaged waveforms of all six patients in the Oz scalp location are shown. Remarkably, the latency decrease was in the order of 7 ms, and the amplitude increase in the order of 30% was observed at 18 weeks in elderly patients.

Discussion
==========

Intravitreal injection of bevacizumab appears to result in significant improvements in visual acuity and a reduction of retinal thickness secondary to exudative AMD.[@b4-opth-7-437],[@b5-opth-7-437],[@b7-opth-7-437] The present results are in line with those of multicenter trials on the effect of bevacizumab in the treatment of exudative AMD. No ocular toxicity or adverse effects were observed in our patients for short-term bevacizumab treatment. Bevacizumab is well tolerated, as was shown in the previous large studies.[@b4-opth-7-437],[@b5-opth-7-437],[@b7-opth-7-437] It is not known why some patients do not respond fully to anti-VEGF therapy. In the present study, the cases P3 and P6 showed only limited response to bevacizumab. AMD is a multifactorial disease that affects the aging process of the RPE cells and their adjacent tissues, and this may play a role in the individual response to treatment.[@b3-opth-7-437] In addition, the delay to receive intravitreal anti-VEGF injection during active exudative AMD process may diminish treatment results.[@b7-opth-7-437] That may be the reason behind the results for cases P3 and P6.

A remarkable decrease in P100 latency and increase in amplitude was observed in the treated eye, but no changes were observed in the untreated eye in the VEP study. The changes in the VEP are most likely due to changes at the macular level. However, if there were no processing changes at all in the higher levels of the visual system, one would expect that in cases in which a large part of the macula stays intact there would be no delay in the onset of the P100 component. Our results ([Figure 2](#f2-opth-7-437){ref-type="fig"}, Patients 1, 2, 3, and 6) show otherwise. Therefore we suggest that the changes in VEP are secondary to changes in the macula. We do however say that VEP is a neurophysiological marker of visual processing. Until now, the effects of intravitreal treatment of AMD in cortical visual processing are largely unknown. In one study of 21 vein occlusion patients successfully treated with bevacizumab injections, VEP were measured only in two patients before injection and at 4 weeks without any significant changes in VEP.[@b8-opth-7-437] However, few reports of the possible changes in the function of visual pathways in diabetes exist. A VEP study using multifocal stimulation (mfVEP) in adult subjects with diabetes showed significantly delayed VEP compared to nondiabetic controls.[@b9-opth-7-437] Diabetic subjects with or without retinopathy demonstrated this delay. This suggests that retinopathy-free patients are showing early neurodegenerative changes occurring either at the level of the retina or upstream in the visual pathway that contribute to a cortical visual response. The mfVEP amplitude measurement appeared to be less sensitive to the effects of diabetes than the latency measurement. Furthermore, a specific analysis of mfVEP indicated that zones with retinopathy showed significantly delayed VEP compared to zones without retinopathy according to Wolff et al.[@b9-opth-7-437] Even in patients without retinopathy, the mfVEP is able to detect preclinical microvascular and/or neurodegenerative changes within or upstream from the retina. Recently a VEP study was also performed in 45 children, 15 with recently discovered juvenile diabetes (DMI), 15 children with long-lasting DMI, and 15 healthy children. Amplitude values decreased progressively, and latency values increased progressively in children with DMI as the years passed.[@b10-opth-7-437]

Thus VEP can detect early signs of diminishing visual ability; however, we were able to detect encouraging VEP modulation within 18 weeks in elderly patients who received intravitreal treatment for AMD. In this study, in most treated eyes, the latencies of P100 were shortened. Since the VEP is covering the whole area of the macula (the healthy part and not only the AMD affected area), the changes of P100 latencies were surprisingly long. One could assume that the healthy part of the macula would produce the signals with normal latencies, and only the affected area would produce longer P100 latencies. It also seems that signals from the healthy part are delayed. This can be interpreted in a way that suggests that there are changes in the visual pathway, and not only in the retina despite the improved vision. Since no VEP changes toward the same direction were observed in the nontreated eye, the finding supports the concept that improved peripheral input plays a significant role in the neural plasticity of the visual cortex. In order to confirm these findings, larger population studies are required, and functional technological analyses are needed.[@b11-opth-7-437],[@b12-opth-7-437]
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![Optical coherence tomographic (OCT) images illustrating retinal thickness of each individual patient (P1--P6) before and after injections (18 weeks in between images).\
**Notes:** For each patient, the top row is before treatment and the bottom row is after treatment. White arrows point to the treated eye and defected sites in the retina. Note that the left eye for P6 was not treated during the study period.\
**Abbreviations:** P, patient; OD, right eye; OS, left eye.](opth-7-437f1){#f1-opth-7-437}

![VEP in the Oz-FCz derivation before (thin line) and after (thick line) anti-VEFG treatment from the treated and nontreated eyes of six patients.\
**Notes:** The waveforms are the average of the about 240 sweeps presented in the two trials. The bars indicate the time ranges over which the curves differ statistically at the probability level of *P* \< 0.05 at least over 8 ms. The dark grey bars correspond to changes consistent with improved vision (ie, with a decrease in P100 latency and/or an increase in P100 amplitude), whereas the light bars correspond to opposite changes. The white bars correspond to changes outside the P100 component. In 5/6 patients, statistically significant changes consistent with improved vision in the treated eye were observed. Note that in P6, there had been a deterioration of vision in the untreated eye between the recordings leading to large changes in VEP from that eye.\
**Abbreviations:** VEP, visual evoked potentials; P, patient number.](opth-7-437f2){#f2-opth-7-437}

![Grand average waveforms of individual waveforms from [Figure 2](#f2-opth-7-437){ref-type="fig"}.\
**Notes:** The improvement due to the treatment is reflected by the shortening of the P100 latency by about 7 ms and by its amplitude increase of about 30%. Due to a small number of subjects in the grand average and their large individual variation, the spread of the average data is so large that the curves and the numbers presented are only for illustration and have no statistical significance.](opth-7-437f3){#f3-opth-7-437}

###### 

Patient characteristics and their visual acuity before and after anti-VEGF treatment

       Gender   Age   BCVA treated eye   BCVA nontreated eye         
  ---- -------- ----- ------------------ --------------------- ----- -----
  P1   F        78    0.2                0.7                   0.7   0.7
  P2   M        90    0.2                0.5                   0.5   0.5
  P3   F        74    0.05               0.3                   0.9   0.9
  P4   F        86    0.5                0.7                   0.8   0.8
  P5   M        75    0.3                0.5                   1.0   0.9
  P6   M        79    0.2                0.4                   0.8   0.5

**Abbreviations:** VEGF, vascular endothelial growth factor; P, patient number; F, female; M, male; BCVA, best corrected visual acuity (Snellen equivalents).

###### 

Retinal thickness (μM) in individual patients measured with optical coherence tomography before and after injection in the treated and nontreated eyes

       Treated eye   Nontreated eye         
  ---- ------------- ---------------- ----- -----
  P1   536           240              253   253
  P2   330           240              250   250
  P3   510           430              250   250
  P4   440           240              240   240
  P5   400           230              250   240
  P6   420           263              263   440

**Abbreviation:** P, patient number.
